Serge Saxonov, the chief executive officer of 10x Genomics, Inc. (NASDAQ:TXG), reported the sale of 15,000 shares of Class A Common Stock in two separate transactions on March 23 and March 24, 2026, according to a recent SEC Form 4 filing. The combined proceeds from the sales amounted to $288,908.
The trades were split across two days. On March 23, Saxonov sold 10,000 shares at a weighted average price of $19.1297, with individual execution prices ranging from $18.78 to $19.41. The following day, March 24, he sold an additional 5,000 shares at a weighted average price of $19.5223, with that day's executions occurring between $19.49 and $19.59.
After these transactions, the filing shows that Mr. Saxonov directly holds 1,172,273 shares of Class A Common Stock. The disclosure notes that the trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan that was adopted on November 29, 2025, indicating the transactions were pre-scheduled rather than ad hoc decisions tied to immediate market developments.
The insider selling took place amid a period of notable share-price appreciation for the company. TXG has advanced more than 103% over the past 12 months and gained approximately 14% in the most recent week noted in the filing, with the stock reported as trading at $20.91 at the time of the filing. Separately, analysis available through InvestingPro is cited in the filing as indicating the stock is trading near its calculated Fair Value, and the platform is presented as a source for additional pro research and valuation tools.
10x Genomics has also been active on the corporate and industry fronts. The company, together with Bioptimus and Broad Clinical Labs, introduced the Spatial Tissue Embedding Learning Atlas (STELA), a project intended to profile up to 100,000 patient tissue specimens across multiple continents. The filing describes STELA as a significant scaling up of spatial biology atlases.
Analyst coverage and institutional activity were also highlighted. Stifel raised its price target for 10x Genomics to $25 and kept a Buy rating, citing strong adoption of the company’s Flex Apex product. Canaccord Genuity increased its price target to $22 following 10x Genomics’ fourth-quarter 2025 financial results, which met prior expectations.
At the same time, the filing notes shifts among institutional holders and investor concerns that could affect sentiment. ARK Invest sold more than 473,000 shares of 10x Genomics, a move characterized as a reallocation of capital away from genomics toolmakers. Wolfe Research pointed to investor unease about the potential implications of Microsoft’s new AI model, GigaTIME, on demand for spatial proteomics, raising questions about competitive dynamics in the sector.
These concurrent developments - executive selling under a Rule 10b5-1 plan, recent product adoption and analyst support, large-scale industry collaborations, and notable institutional selling - paint a complex picture for 10x Genomics as it navigates growth and shifting investor positioning within the genomics tools market.
Key data from the Form 4 filing:
- Total shares sold: 15,000
- Total proceeds: $288,908
- March 23 trade: 10,000 shares at weighted average $19.1297 (range $18.78 - $19.41)
- March 24 trade: 5,000 shares at weighted average $19.5223 (range $19.49 - $19.59)
- Post-sale direct ownership: 1,172,273 Class A shares
- Trading plan: Rule 10b5-1 plan adopted November 29, 2025